NCT04730544 - Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions

Colorectal Cancer MetastaticMSI-H Colorectal Cancer

Interventions

DRUG

Nivolumab 480mg + Ipilimumab

Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w

DRUG

Nivolumab 240 mg + Ipilimumab

induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w

Trial Locations (19)

Institut Sainte Catherine, Avignon

CHU Jean Minjoz, Besançon

CHU Morvan, Brest

Hôpital Henri Mondor, Créteil

Centre Georges François Leclerc, Dijon

Clinique Victor Hugo-Centre jean Bernard, Le Mans

Hopital Franco-Britannique - Fondation Cognacq-Jay, Levallois-Perret

CHRU Lille, Lille

Centre Léon Bérard, Lyon

Hôpital Privé Jean Mermoz, Lyon

Hôpital de la Timone, Marseille

ICM Val d'Aurelle, Montpellier

CHU Nantes- Hôtel Dieu, Nantes

Hôpital Saint Antoine, Paris

Institut Mutualiste Montsouris, Paris

CHU Bordeaux - Hôpital Haut Lévêque, Pessac

CHU Poitiers, Poitiers

Hôpital Robert Debré, Reims

CHU Toulouse - IUCT Rangueil -Larrey, Toulouse